Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis: A Randomized Clinical Trial

There is evidence that sodium benzoate (BZ) may be an effective adjunctive treatment for schizophrenia. The clinical efficacy of BZ has been investigated in chronic schizophrenia; however, the efficacy of this agent has not been studied in individuals with early psychosis. To examine the clinical ef...

Full description

Saved in:

Bibliographic Details
Published in:	JAMA network open Vol. 3; no. 11; p. e2024335
Main Authors:	Scott, James G, Baker, Andrea, Lim, Carmen C W, Foley, Sharon, Dark, Frances, Gordon, Anne, Ward, David, Richardson, Drew, Bruxner, George, Beckmann, K Martin, Hatherill, Sean, Stathis, Stephen, Dixon, Krystal, Ryan, Alexander E, McWhinney, Brett C, Ungerer, Jacobus P J, Berk, Michael, Dean, Olivia M, Saha, Sukanta, McGrath, John
Format:	Journal Article
Language:	English
Published:	United States American Medical Association 02-11-2020
Subjects:	Adolescent Adult Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Australia - epidemiology Case-Control Studies Clinical trials Drug Therapy, Combination Female Humans Male Online Only Original Investigation Placebos - administration & dosage Psychiatric Status Rating Scales - statistics & numerical data Psychiatry Psychosis Psychotic Disorders - drug therapy Psychotic Disorders - psychology Quality of Life Schizophrenia Schizophrenia - drug therapy Sodium Benzoate - administration & dosage Sodium Benzoate - adverse effects Treatment Outcome Young Adult Australia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	There is evidence that sodium benzoate (BZ) may be an effective adjunctive treatment for schizophrenia. The clinical efficacy of BZ has been investigated in chronic schizophrenia; however, the efficacy of this agent has not been studied in individuals with early psychosis. To examine the clinical efficacy of the adjunctive use of BZ for symptoms in people with early psychosis. Using a placebo-controlled double-masked parallel-group design, this randomized clinical trial was conducted from August 2015 to July 2018. Participants aged between 15 and 45 years experiencing early psychosis were enrolled from 5 major clinical sites in Queensland, Australia. Data analysis was conducted from October 2018 to February 2020. Participants were randomized 1:1 (50 participants in each group) to receive 500 mg of sodium benzoate twice daily or placebo for 12 weeks. The primary efficacy outcome was the Positive and Negative Syndrome Scale (PANSS) total score at 12 weeks. The key secondary efficacy measures were (1) the Clinical Global Impression score, (2) the Hamilton Depression Rating Scale for depression, (3) functioning as assessed by the clinician-rated Global Assessment of Function, and (4) the Assessment of Quality of Life Scale. The PANSS subscale scores and impact on selected amino acid concentrations were also assessed. The study comprised 100 participants with a mean (SD) age of 21.4 (4.1) years, of whom 73 (73%) were male individuals. The mean (SD) baseline PANSS score was 75.3 (15.4). We found no improvement in total PANSS score in the BZ group compared with the placebo group. The end result of least-squares mean difference (SE) for total PANSS was -1.2 (2.4) (P = .63). There were no differences in any subscales of the PANSS, any secondary measures, nor any amino acid concentrations. The dose of BZ was well tolerated without any clinically significant treatment-emergent adverse event differences between BZ and placebo groups. In this randomized clinical trial, there was no evidence that adjunctive use of 500 mg of BZ twice daily is an effective treatment for individuals with early psychosis. anzctr.org.au Identifier: ACTRN12615000187549.
ISSN:	2574-3805 2574-3805
DOI:	10.1001/jamanetworkopen.2020.24335